CytoDyn Inc. (OTCMKTS:CYDY - Get Free Report)'s share price fell 2.8% during mid-day trading on Friday . The company traded as low as $0.30 and last traded at $0.31. 1,160,634 shares changed hands during trading, a decline of 11% from the average session volume of 1,303,785 shares. The stock had previously closed at $0.32.
CytoDyn Stock Performance
The stock has a fifty day moving average of $0.32 and a 200-day moving average of $0.24. The company has a market cap of $387.69 million, a PE ratio of -31.04 and a beta of 1.29.
CytoDyn Company Profile
(
Get Free Report)
CytoDyn Inc, a clinical-stage biotechnology company, engages in the development of treatments for multiple therapeutic indications. The company is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19, human immunodeficiency virus (HIV), Metabolic dysfunction-associated steatohepatitis (MASH), and solid tumors in oncology, such as metastatic triple-negative breast cancer.
See Also
Before you consider CytoDyn, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CytoDyn wasn't on the list.
While CytoDyn currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
